Caribou Biosciences, Inc. (CRBU) stock
CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3074% below fair value
$0.33−0.01 (-4.29%)
Close on Nov 18, 2026Market cap $34.96MP/E –Yield –
Caribou Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Caribou Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$109.47M. For fiscal 2025 it was -$148.34M. The highest annual figure on record is -$34.31M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$148.34M | – |
| FY2024 | Dec 31, 2024 | -$166.62M | – |
| FY2023 | Dec 31, 2023 | -$116.06M | – |
| FY2022 | Dec 31, 2022 | -$106.40M | – |
| FY2021 | Dec 31, 2021 | -$66.98M | – |
| FY2020 | Dec 31, 2020 | -$36.12M | – |
| FY2019 | Dec 31, 2019 | -$34.31M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$25.34M | – |
| Q1 FY2026 | Mar 31, 2026 | -$26.28M | – |
| Q4 FY2025 | Dec 31, 2025 | -$28.45M | – |
| Q3 FY2025 | Sep 30, 2025 | -$29.40M | – |
| Q2 FY2025 | Jun 30, 2025 | -$47.58M | – |
| Q1 FY2025 | Mar 31, 2025 | -$42.91M | – |
| Q4 FY2024 | Dec 31, 2024 | -$38.88M | – |
| Q3 FY2024 | Sep 30, 2024 | -$38.24M | – |
| Q2 FY2024 | Jun 30, 2024 | -$43.50M | – |
| Q1 FY2024 | Mar 31, 2024 | -$46.00M | – |
| Q4 FY2023 | Dec 31, 2023 | -$37.44M | – |
| Q3 FY2023 | Sep 30, 2023 | -$14.63M | – |
| Q2 FY2023 | Jun 30, 2023 | -$32.87M | – |
| Q1 FY2023 | Mar 31, 2023 | -$31.12M | – |
| Q4 FY2022 | Dec 31, 2022 | -$30.58M | – |
| Q3 FY2022 | Sep 30, 2022 | -$26.54M | – |
| Q2 FY2022 | Jun 30, 2022 | -$28.43M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.85M | – |
| Q4 FY2021 | Dec 31, 2021 | -$20.41M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.62M | – |
| Q2 FY2021 | Jun 30, 2021 | -$15.96M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.18M | – |
| Q4 FY2020 | Dec 31, 2020 | -$15.21M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.23M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.26M | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.43M | – |
See a number that looks wrong?